ALGS - Company ID 0001799448
The table below shows Aligos Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.83M | $741.00K | $965.00K | $311.00K | $1.25M | $1.06M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $23.35M | $23.94M | $13.98M | $14.50M | $16.77M | $21.10M |
Aligos Therapeutics, Inc. reported annual revenue of $2.19M for fiscal year 2025. That is down 39.5% from $3.61M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $6.41M |
| $5.17M |
| $5.56M |
| $5.05M |
| $4.63M |
| $6.38M |
| Operating income | -$26.93M | -$28.36M | -$18.57M | -$19.24M | -$20.13M | -$26.41M |
| Income tax | $317.00K | $56.00K | $185.00K | $43.00K | $91.00K | $189.00K |
| Net income | -$23.04M | -$31.54M | -$15.86M | $43.09M | -$19.26M | $5.06M |
| EPS (diluted) | -$2.21 | -$3.04 | -$1.53 | -$2.11 | -$3.07 | $0.81 |